财中社1月12日电微创脑科学(02172)发布公告,预计截至2024年12月31日的年度净利润将在2.36亿元至2.7亿元之间,较上年同期增长约75%至100%。公司指出,这一显著增长主要得益于医院覆盖及市场份额的提升,以及海外业务收入的翻倍增长,预计整体收入将实现双位数增长。
此外,公司通过实施供应链改善和成本节约措施,提升了运营效率,显著增强了盈利能力。公告中提到,2020年度至2024年度的经调整净利润实现了约55%的年复合增长率。公司仍在准备2024年度的全年业绩,相关公告预计将在2025年3月底发布,提醒股东和潜在投资者在买卖公司股份时保持谨慎。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.